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Abstract 
Introduction: Thymic epithelial tumors (TETs) are associated with paraneoplastic autoimmune 
(PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with 
TETs.   
 
Methods: The International Thymic Malignancy Interest Group (ITMIG) retrospective database 
was examined to determine (i) baseline and treatment characteristics associated with PN/AI 
syndromes and (ii) the prognostic role of PN/AI syndromes for patients with TETs. The 
competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the 
Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards 
model was used for multivariate analysis. 
 
Results: 6670 patients with known PN/AI syndrome status were identified from 1951-2012. 
PN/AI syndromes were associated with younger age, female sex, type B1 thymoma, earlier 
stage, and an increased rate of total thymectomy and complete resection status. There was a 
statistically significant lower CIR in the PN/AI (+) group compared to the PN/AI (-) group (10-
year 17.3% vs. 21.2%, respectively, p=0.0003). The OS was improved in the PN/AI (+) group 
compared to the PN/AI (-) group (HR 0.63, 95% CI 0.54-0.74, P<0.0001, median OS 21.6 years 
versus 17.0 years, respectively). However, in the multivariate model for recurrence-free survival 
and OS, PN/AI syndrome was not an independent prognostic factor.  
 
Discussion: Previously, there has been mixed data regarding the prognostic role of PN/AI 
syndromes for patients with TETs. Here, using the largest dataset in the world for TETs, PN/AI 
syndromes were associated with favorable features (i.e. earlier stage, complete resection 
status) but were not an independent prognostic factor for TETs.  
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Abbreviations: AChR  = acetylcholine receptor; AIRE = autoimmune regulator; ChART  = 
Chinese Alliance for Research in Thymomas; CIR = cumulative incidence of recurrence; ESTS 
= European Society of Thoracic Surgeons; IASLC = International Association for the Study of 
Lung Cancer; ITMIG = International Thymic Malignancy Interest Group; JART = Japanese 
Association for Research on the Thymus; KART = Korean Association for Research on the 
Thymus; MG = myasthenia gravis; MGFA = Myasthenia Gravis Foundation of America; MHC II 
= major histocompatibility class II; NETT = neuroendocrine tumors of the thymus; OS = overall 
survival; PN/AI = paraneoplastic autoimmune; PN/AI (+) = presence of paraneoplastic 
autoimmune syndrome; PN/AI (-) = absence of paraneoplastic autoimmune syndrome; RFS = 
recurrence-free survival; RyR  = ryanodine receptor; TETs = thymic epithelial tumors; WHO = 
World Health Organization  
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Introduction:  
Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas, are rare tumors of 
the anterior mediastinum.1 Thymomas have been associated with paraneoplastic autoimmune 
(PN/AI) syndromes more frequently than have thymic carcinomas.2 Paraneoplastic syndromes 
can precede the diagnosis of a tumor and tend to improve with treatment of the tumor. Although 
myasthenia gravis (MG) is the most common PN/AI syndrome associated with TETs,3 there are 
others related to hematopoietic cells, including pure red cell aplasia4 and 
hypogammaglobulinemia.5 There are many additional PN/AI syndromes reported as case 
reports such as systemic lupus erythematosus.6  
 
With regards to MG, 10-20% of patients with MG have thymoma and 30% of patients with 
thymoma either present with or develop MG.3, 7 Myasthenia gravis is a result of autoantibodies 
against the neuromuscular junction, with the most common being acetylcholine receptor (AChR) 
antibodies.3 The hallmark MG symptoms of skeletal muscle weakness and fatigability can range 
from isolated ocular symptoms to more generalized symptoms.7 There are specific antibodies 
associated with MG that co-exist with AChR antibodies8 and increase the likelihood of a co-
existing thymoma and may herald more severe disease, including antibodies against titin9, a 
large intracellular protein important for muscle contractility, and against ryanodine receptor 
(RyR), a calcium channel in the sarcoplasmic reticulum.10 Although autoantibodies play a critical 
role in the development of MG in patients with thymoma, there are seronegative cases reported, 
implicating alternative mechanisms of immune dysregulation.11, 12 
 
Although the exact pathogenesis remains unknown, it is not surprising that TETs are associated 
with autoimmune disorders, given that the thymus is critical in building the T-cell repertoire (i) 
via positive selection in thymic cortical epithelial cells and (ii) in maintaining immune 
homeostasis and central self-tolerance via negative selection in the thymic medulla.13 
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Thymomas have a deranged tumor microenvironment, carry out abnormal intratumoral 
thymopoiesis, and thus disseminate an abnormal circulating T-cell repertoire that has been 
insufficiently tolerized to self-antigens.14, 15 For example, one study showed that patients with 
thymoma-associated MG had increased circulating mature CD4+/CD45RA+ T-cells, and another 
study showed that they had decreased regulatory T-cells compared to patients with thymoma 
without MG.16, 17 Also, autoimmune regulator (AIRE), a protein that regulates expression of self-
antigens in the thymic medulla and plays a critical role in central tolerance,18 is absent in the 
vast majority (>95%) of thymomas.19 Finally, thymoma epithelial cells have decreased major 
histocompatibility class II (MHC II) expression, which in conjunction with decreased self-antigen 
expression results in a biased T-cell repertoire.20  
 
In the current study, we examined patients with TETs, including thymomas, thymic carcinomas, 
and neuroendocrine tumors of the thymus (NETT), with PN/AI syndrome status recorded in the 
International Thymic Malignancy Interest Group (IT IG) retrospective database. 21 Our 
objectives were two-fold: (i) to determine patient, tumor, and treatment characteristics 
associated with PN/AI syndromes and (ii) to determine whether the presence of PN/AI 
syndrome is an independent prognostic factor for patients with TETs.  
 
Materials and Methods: 
The ITMIG retrospective database of thymic malignancies is the result of an international 
collaboration of 56 institutions, which has been described in detail elsewhere.21 This study was 
conducted with use of a limited dataset with de-identified information and therefore, without 
requirement of authorization or documentation of waiver of the institutional review board. After 
execution of a data use agreement, a limited dataset from each institution was provided to 
ITMIG for the sole purpose of research. Only the ITMIG statistical core and selected members 
of the database committee had full access to the data (X.Y., Y.S., A.A., F.D., J.H.).  
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Of 7795 patients in the ITMIG retrospective database from 1951-2012, we identified 6670 with 
known paraneoplastic/autoimmune (PN/AI) syndrome status at initial diagnosis and known 
pathologic diagnosis of thymoma, thymic carcinoma, and NETT. The final sample size was 6297 
patients (Figure 1).  The PN/AI syndrome data field terms included myasthenia gravis, pure red 
cell aplasia, hypogammaglobulinemia, and other. Only “other” PN/AI syndromes with further 
description were included in the analysis. The vast majority (97%) of patients in this cohort were 
from the time period 1991 onwards. Patient, tumor, and treatment characteristics were collected. 
Each contributing site to the database reported histology per 2004 World Health Organization 
(WHO) classification,22 and there was no central pathology review. Patients with histology of 
metaplastic, micronodular, or “other” without further specification were excluded. There were 
only 90 cases of micronodular thymoma and 16 cases of metaplastic thymoma in the database. 
Of the cases with micronodular and metaplastic thymoma, 3 and 1 had a PN/AI syndrome, 
respectively, with missing information on PN/AI syndrome status in 58% and 50%, 
respectively.    
 
Pathologic stage was described by Masaoka staging,23 Masaoka-Koga staging,24 or Masaoka-
Koga staging with ITMIG clarifications.25 The ITMIG/International Association for the Study of 
Lung Cancer (IASLC) staging project demonstrated no difference in outcomes between stage 
IIA and IIB patients or between Masaoka and Masaoka-Koga staging systems.26 Therefore, 
stage IIA, IIB, and II were categorized as stage II for the purpose of analyses. Given the 
differences in outcomes observed between stage IVA and IVB patients,26 cases with “stage IV” 
disease without further subset clarification were excluded.  
 
Statistical Analyses  
All analyses were performed with SAS 9.3 software (SAS Institute Inc., Cary, NC, USA) and R 
version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics 
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were used to summarize the baseline and treatment characteristics, including continuous 
variables as medians and ranges, and categorical variables as frequencies and relative 
percentages.  The Chi-square test and t-test were used to compare categorical variables and 
continuous variables, respectively, between patients who had paraneoplastic/autoimmune 
syndromes [PN/AI (+)] and patients who did not [PN/AI (-)].  The competing risks model was 
used to estimate the thymic malignancy recurrence-free survival (RFS), which was measured 
from the date of intervention to the date of death or date of malignancy recurrence, whichever 
occurred first, and censored at the date patient last known to be alive without recurrence. In the 
competing risks model, death was included as the competing event, though curves of death are 
not shown in the cumulative incidence plots. The difference in RFS between PN/AI (+) patients 
and PN/AI (-) patients was assessed using Gray’s test.27 The Kaplan-Meier method was used to 
calculate the overall survival (OS), which was measured from the date of intervention to the date 
of death, and censored at the date patient last known to be alive. The log rank test was used to 
compare OS of PN/AI (+) patients and PN/AI (-) patients. Outcomes were also examined 
stratified by PN/AI syndrome status in subsets of thymoma and thymic carcinoma, stage 
subsets, and time periods.  
 
A Cox proportional hazards model for multivariate analysis of RFS and OS included all factors 
detailed in Table 1 including age, sex, continent (North America, South America, Asia, Europe), 
pathology (thymoma, thymic carcinoma, NETT), WHO subtype (A, AB, B1, B2, B3), pathologic 
stage (I, II, III, IVA, IVB), extent of thymectomy (none, partial, total, extended), chemotherapy 
(curative, palliative/none), radiation (curative, palliative/none), and resection status (R0, R1, 
R2).  Patients with missing data were excluded from this analysis; no imputations were 
performed. A two-sided P-value of <0.05 was considered statistically significant for any 
statistical test employed. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Results:  
Full Cohort Characteristics 
A total of 6297 patients were included in the analysis (Figure 1).  Cohort characteristics are 
reported in Table 1. The majority of patients were from Asia (42%) followed by Europe (33%) 
and North America (25%). As expected, thymoma pathology predominated (86%), with the most 
common histotypes being AB and B2. Thymic carcinoma was relatively well–represented (12%) 
in this cohort but NETT was rare (2%). Approximately one-third of patients had a PN/AI 
syndrome, with the vast majority being MG. However, there were also cases of pure red cell 
aplasia (n=47) and hypogammaglobulinemia (n=13). Pathologic stage was biased towards early 
stage I-II disease, representing two-thirds of the cohort. Almost all patients (99%) underwent 
surgery, with most patients undergoing a total thymectomy (81%) and achieving a complete R0 
resection (84%). 
 
Baseline and Treatment Characteristics associated with Paraneoplastic Autoimmune 
Syndromes 
Patients with PN/AI syndrome [PN/AI (+)] were younger (median age 50 years-old) and 
predominantly female and European (Table 1). Patients without PN/AI syndrome [PN/AI  (-)] 
were older (median age 55 years-old) and predominantly male and Asian. In both PN/AI (+) and 
PN/AI (-) groups, the most common pathology was thymoma. However, the most common 
thymoma WHO histotype was B2 for the PN/AI (+) group and AB for the PN/AI (-) group. In 
addition, the PN/AI (-) group also had a higher proportion of thymic carcinoma histology (17% vs. 
2%, respectively). Pathologic stage was mostly early stage I-II in both PN/AI (+) and PN/AI (-) 
groups, however, the PN/AI (-) group had a higher proportion of advanced stage III-IVB disease. 
Both PN/AI (+) and PN/AI (-) groups most commonly underwent a total thymectomy, received no 
(or palliative) chemotherapy, no (or palliative) radiotherapy, and achieved a complete R0 
resection. However, when comparing the PN/AI (+) group to the PN/AI (-) group, the rate of total 
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thymectomy, no (or palliative) chemotherapy, and complete R0 resections was higher. There 
was no difference in radiation practices between the groups. The findings of this analysis were 
the same when only examining the PN/AI syndrome of MG (data not shown). 
 
Cumulative Incidence of Recurrence (CIR) and Overall Survival (OS) 
The median follow-up for the whole group was 3.7 years. The median follow-up for the PN/AI (+) 
group was 4.4 years and for the PN/AI (-) group was 3.3 years. Recurrence-free survival (RFS) 
information was available on 4375 patients. Overall, there was a statistically significant lower 
CIR in the PN/AI (+) group compared to PN/AI (-) group (p=0.0003; Figure 2): 10-year, 17.3% vs. 
21.2%, respectively; 20-year, 27.2% vs. 28.1%, respectively; 30-year, 29.5% vs. 39.4%, 
respectively; and 40-year, N/A vs. 29.5%, respectively. There was no difference in CIR between 
PN/AI (+) and PN/AI (-) groups when examining the subgroups of thymoma (p=0.93), thymic 
carcinoma (p=0.76) (Supplementary Data Fig.1-2), and stage (Supplementary Data Fig.3-7). 
 
Survival information was available on 4962 patients. In the overall population, OS was improved 
in the PN/AI (+) group compared with the PN/AI (-) group (HR 0.63, 95% CI 0.54-0.74, 
P<0.0001, median OS 21.6 years vs. 17.0 years, respectively; Figure 3). In the thymoma 
subgroup, there was a statistically significant improvement in OS for the PN/AI (+) group versus 
the PN/AI (-) group (HR 0.82, 95% CI 0.70-0.97, p=0.02) (Figure 4A). In the thymic carcinoma 
subgroup, there was also a trend for improved OS in the PN/AI (+) group (HR 0.56, 95% CI 
0.29-1.10, p=0.09), with the survival curves separating early (Figure 4B). When stratified by 
stage, the improved OS in the PN/AI (+) group compared to the PN/AI (-) group remained in the 
stage III and stage IVB subgroups (Supplementary Data Fig.8-12). The above analyses of CIR 
and OS were also repeated for patients who only had MG and the results were the same (data 
not shown).  
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Survival was also examined over three time periods, 1951-1970, 1971-1990, and 1991-2012, 
which included 50, 228, and 5678 patients, respectively, with a prevalence of PN/AI syndrome 
of 70.0%, 52.2%, and 32.0%, respectively. For the PN/AI (+) group, the OS was significantly 
improved in the most recent time period (p=0.001; Supplementary Data Fig.13). However, for 
the PN/AI (-) group, there was no difference in OS among the different time periods (p=0.87).  
 
Multivariate Model for Recurrence-Free Survival and Overall Survival 
There was complete data available on 2193 patients and 2352 patients for the multivariate 
analysis of RFS and OS, respectively. In a multivariate model (Table 2), the following 
characteristics were independently associated with increased recurrence: older age, histology of 
thymic carcinoma and NETT, advanced stage III-IVB disease, larger tumor size, and R2 
resection status.  Characteristics independently associated with decreased recurrence included: 
Asia continent and receipt of curative radiation (i.e. neoadjuvant, adjuvant, and definitive setting).  
In a multivariate model, the following characteristics were independently associated with worse 
OS: older age, histology of thymic carcinoma and NETT, advanced stage III-IVB disease, 
receipt of curative chemotherapy (i.e. neoadjuvant, adjuvant, and in definitive setting with 
radiation), and R2 resection status. Characteristics independently associated with improved OS 
included: receipt of curative radiation and B1 histotype. The presence of PN/AI syndrome was 
not independently associated with clinical outcomes of RFS and OS.  
  
Discussion:  
To our knowledge, this is the largest study and the first multi-continent study, examining PN/AI 
syndromes in patients with TETs. This was achieved using the International Thymic Malignancy 
Interest Group (ITMIG) retrospective database, which serves as a paradigm for performing 
research in rare malignancies. Previously, there has been conflicting data about the prognostic 
role of PN/AI syndromes for TETs.28 Our main finding is that the presence of PN/AI syndromes 
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[PN/AI(+)] was associated with favorable prognostic factors but was not an independent 
prognostic factor for recurrence-free survival (RFS) or overall survival (OS) for patients with 
TETs. Our results were identical when only examining the PN/AI syndrome of MG (data not 
shown), which as expected comprised the majority (96%) of PN/AI syndromes in this cohort. 
Given the small numbers of pure red cell aplasia and hypogammaglobulinemia, we were not 
able to independently assess the clinical impact of these syndromes and thus, they were 
analyzed in aggregate with MG. In the ITMIG cohort, approximately one-third of patients with 
TETs had a PN/AI syndrome.29 This is similar to the prevalence of MG reported in national 
retrospective database studies29, including Japanese Association for Research on the Thymus 
(JART)30, European Society of Thoracic Surgeons (ESTS)31, and Chinese Alliance for Research 
in Thymomas (ChART)32. There is overlap with these national databases and our ITMIG 
database cohort, including 31% cases from the ChART database and 14% cases from the 
ESTS database (Supplementary Data Fig.14), while the JART database was not included. 
 
PN/AI Syndrome and Patient, Tumor, and Treatment Factors 
In our cohort, the PN/AI (+) group was associated with known favorable prognostic factors. In 
regards to demographic factors, the PN/AI (+) group was younger in age by a median of 5 years 
and had a higher proportion of female sex, confirming prior findings in the literature.30, 32-34   In 
regards to pathology, the PN/AI (+) group had a higher proportion of favorable histology 
thymoma, and a lower proportion of thymic carcinoma. Type B2 was the most common 
thymoma histotype (37%) in the PN/AI (+) group, while type AB (30%) was the most common in 
the PN/AI (-) group. These thymoma histotypes have also been previously identified as the most 
common when stratified by PN/AI syndrome status35 in the JART30 and ChART databases.32 
The consistent association of PN/AI syndromes with type B2 thymoma across large database 
studies may be explained by B2 thymomas containing heavy lymphocyte regions, including 
CD4+CD8+ double-positive T-cells that are vulnerable to altered positive selection in the setting 
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of thymic epithelial cells with low expression of HLA-DR.36 Of note, 6% of patients in our cohort 
with thymic carcinoma had a PN/AI syndrome. An increasing number of thymic carcinomas with 
PN/AI syndromes are being reported,30, 32, 34 including a 12% prevalence of MG in a single 
institution series of 49 patients.37 It is possible since there was no central pathology review in 
the ITMIG retrospective database that a proportion of thymomas were misclassified as thymic 
carcinomas since poor inter-observer reproducibility has been demonstrated between B3 
thymoma and thymic carcinoma.38 We also reported that 4% of NETTs had MG, which has been 
rarely reported in the literature.32, 39  
 
The PN/AI (+) group also had a higher rate of earlier stage disease and complete R0 resections, 
which has been described previously.30-34 Innumerable studies have shown that stage and 
resection status are the strongest independent prognostic factors for patients with TETs.30-32 
The likelihood of a complete resection is also higher with earlier stage disease.31, 32, 40  PN/AI (+) 
TETs may be caught at an earlier stage due to the presence of symptoms, and it is also 
possible that PN/AI (+) TETs are associated with better biology.35  
 
In regards to treatment, a higher proportion of patients in the PN/AI (+) group underwent a total 
thymectomy [90% PN/AI (+) vs. 77% PN/AI (-)]. It has been hypothesized that to increase the 
chances of remission of MG, a total thymectomy is required. This was recently supported by the 
results of an international randomized trial demonstrating thymectomy, including en bloc 
resection of all mediastinal tissue containing either gross or microscopic thymic tissue, is more 
beneficial than prednisone therapy alone for the treatment of non-thymomatous MG.41 Despite 
Myasthenia Gravis Foundation of America (MGFA) status at diagnosis42 (i.e. describing severity 
of MG symptoms) and MGFA post intervention status (i.e. clinical state after treatment such as 
thymectomy) being collected for the ITMIG database, it was not done consistently. Therefore, 
we cannot comment on how surgical intervention affected the severity of MG symptoms in our 
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cohort. Preoperative MGFA classification was examined in the JART database and showed no 
difference in recurrence or survival for thymomas when stratified by MGFA classification.30  In a 
systematic review, MGFA status indicating mild disease preoperatively enhanced the chance of 
complete MG remission after thymectomy.43 Partial thymectomy can be considered in patients 
with early stage tumors without MG since prior retrospective studies have shown similar 
recurrence rates for partial versus total thymectomy in this group.44, 45 This could account for the 
higher proportion of partial thymectomies performed in the PN/AI (-) group of our cohort.  
 
PN/AI Syndrome, Recurrence, and Survival   
The PN/AI (+) group had statistically significant improved outcomes compared to the PN/AI (-) 
group for cumulative incidence of recurrence (CIR) and overall survival (OS) in the overall 
cohort. However, when performing the analysis in thymoma, thymic carcinoma, and stage 
subgroups, there was no difference in CIR between the PN/AI (+) and PN/AI (-) groups, 
indicating that these may be confounding factors.  When performing the same subgroup 
analyses for OS, the improved OS for patients with PN/AI syndrome remained significant in the 
thymoma subgroup, trended in the thymic carcinoma subgroup, and remained significant in 
advanced stage III and IVB disease. The trend for improved OS in PN/AI (+) thymic carcinoma 
has been shown in other series probably due to the association with favorable prognostic 
factors including smaller tumors, earlier Masaoka stage, and higher rates of complete 
resection.37 The improved OS in advanced stage disease suggests that the presence of PN/AI 
syndromes may indicate better biology or a type of selection bias among advanced stage 
tumors that is not readily identified in this retrospective cohort.  In regards to time period, we 
found that the PN/AI (+) group had significantly improved OS in the most recent time period 
(1991-2012) but there was no difference in OS in the PN/AI (-) group over time. This 
observation is possibly due to improved treatment and supportive care of MG, as reports prior to 
the 1980s showed that MG negatively impacted OS for patients with TETs.28  
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The most important finding in our study is that PN/AI syndrome status was not an independent 
factor associated with RFS or OS in a multivariate model. Independent factors associated with 
RFS and OS in this study included age (older age worse), histology (non-thymoma histology 
worse), stage (advanced stage III-IVB worse), and resection status (incomplete R2 resection 
status worse). PN/AI syndrome status was likely not an independent prognostic factor because 
of its association with these strong prognostic factors. Additional unfavorable factors found in 
the multivariate analysis for RFS and OS was larger size46 and receipt of chemotherapy, 
respectively. The latter could be because chemotherapy agents (i.e. anthracyclines) have long-
term toxicities including cardiomyopathy and secondary malignancies. Curative intent radiation 
was an independent favorable factor for both RFS and OS, possibly because radiation is 
capable of destroying microscopic islands of thymus not surgically excised. Independent 
favorable features for RFS included Asian continent and for OS included type B1 thymoma.   
 
There are limitations of the recurrence and survival analyses in our study. The recurrence 
analysis was limited by the likely variable frequency of follow-up imaging at each institution and 
thus, when a recurrence was first detected. The ITMIG standards recommend follow-up after 
surgical resection with a computed tomography (CT) chest each year for 5 years and thereafter, 
alternating chest x-ray and CT chest until year 11, at the minimum.47  However, these follow-up 
standards were not likely applied given the cohort spanned multiple countries and was 
retrospective in nature. Limitations of the OS analysis for our study included (i) a significant 
proportion of missing data for cause of death (>90% missing), (ii) the relatively short median 
follow-up time of the group (< 4 years), and (iii) lead time bias since patients with PN/AI 
syndrome may be diagnosed earlier. 
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Here, we place our findings in the context of the existing literature. Similar to our study, the 
ChART database demonstrated a decreased rate of recurrence in patients with MG even in 
those with advanced Masaoka stage III/IV disease (15.7% vs. 31.7%, respectively), although 
there were significantly lower rates of thymic carcinoma and smaller tumor size in the MG cohort. 
32
 However, the JART database showed similar recurrence-free interval in patients with and 
without MG (5-year 93% vs. 92% and 10-year 89% vs. 87%, respectively), although only 
patients with thymoma were included in this analysis.30 Of these databases, the ESTS database 
was the only one that examined recurrence in a multivariate model and unlike our study, 
showed that MG was an independent prognostic factor associated with lower CIR.31 Similar to 
our study, the ChART authors observed OS was improved in patients with MG with advanced 
stage III/IV disease but unlike our study, they also found that OS was worse in patients with MG 
with stage I disease.32 Across the ChART,32 ESTS,31 and JART30 databases, the PN/AI 
syndrome of MG in TETs was not an independent prognostic factor for OS in multivariate 
analyses.  
 
Conclusions 
We have used the largest and only multi-continent database for TETs to clarify the controversial 
prognostic role of PN/AI syndromes.28 Despite the strength in numbers of this study, it has the 
standard limitations of a retrospective database including missing information and selection bias. 
We found PN/AI syndromes to be associated with favorable features such as younger age, type 
B1 thymoma, earlier stage, and increased rate of complete resection status. However, the 
presence of PN/AI syndrome was not an independent prognostic factor for TETs for either RFS 
or OS. Importantly, our study confirms prior national database studies that PN/AI syndrome 
status (represented by MG in these studies) is not an independent factor associated with OS.30, 
32,30, 31
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Figure Captions 
Figure 1:  Flow Diagram. *Numbers do not add up to 373 because there is overlap among 
patients with missing information for each variable. (PN/AI=paraneoplastic/autoimmune 
syndrome)  
 
Figure 2: Cumulative Incidence of Recurrence in All Patients, PN/AI (+) vs. PN/AI (-) 
(PN/AI=paraneoplastic/autoimmune syndrome) 
 
Figure 3: Overall Survival in All Patients, PN/AI (+) vs. PN/AI (-) 
(PN/AI=paraneoplastic/autoimmune syndrome) 
 
Figure 4: Overall Survival, PN/AI (+) vs. PN/AI (-), in (A) Thymoma Patients and (B) Thymic 
Carcinoma Patients (PN/AI=paraneoplastic/autoimmune syndrome)  
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Table 1: Cohort Characteristics of 6297 Patients from ITMIG Retrospective Database  
Characteristic   Total Cohort 
n=6297 
PN/AI (+) 
n=2143 
PN/AI (-) 
 n=4154 
p-value 
Age median-years (range) 53 (5-89) 50 (5-89) 55 (7-88) p<0.0001 
Size median centimeters (range) 6.0 (0.1-30) 5.0 (0.1-22) 6.5 (0.3-30) p<0.0001 
Sex 
   Male 
   Female  
   Missing 
 
3258  (51.8)  
3035  (48.2) 
4 
 
1010  (47.2) 
1131  (52.8) 
-- 
 
2248  (54.1) 
1904  (45.9) 
-- 
 
p<0.0001 
Continent 
   North America 
   South America 
   Asia 
   Europe 
 
1555  (24.7) 
54      (0.9) 
2635  (41.9) 
2053  (32.6) 
 
425    (19.8) 
33      (1.5) 
683    (31.9) 
1002  (46.8) 
 
1130  (27.2) 
21      (0.5) 
1952  (47.0) 
1051  (25.3) 
 
p<0.0001 
PN/AI 
   Yes 
    Myasthenia Gravis 
    Pure Red Cell Aplasia 
    Hypogammaglobulinemia 
    Other 
  No 
 
2143   (34.0) 
2068   (32.8) 
47        (0.7) 
13        (0.2) 
15        (0.3) c 
4154   (65.4) 
 
 
 
--- 
 
 
 
--- 
 
 
 
--- 
Pathology 
   Thymoma 
   Thymic Carcinoma 
   NETT  
   Missing 
 
5306  (86.1) 
717    (11.6) 
139    (2.3) d 
135 
 
2061  (97.7)  
42      (2.0) d 
5        (0.2) d 
-- 
 
3245  (80.0) 
675    (16.7) 
134    (3.3)   
-- 
 
p<0.0001 
WHO Histology 
   A 
   AB 
   B1 
   B2 
   B3    
   Missing 
 
525   (10.7) 
1211 (24.7) 
897   (18.3) 
1329 (27.1) 
943   (19.2) 
1392 
 
145   (7.6)  
325   (17.0) 
343   (17.9) 
708   (37.0) 
394   (26.0) 
-- 
 
380    (12.7) 
886    (29.6) 
554    (18.5) 
621    (20.8) 
549    (18.4) 
-- 
 
p<0.0001 
Pathologic Stage 
   I 
   II 
 
1986  (36.5) 
1672  (30.7) 
 
682   (36.9) 
695   (37.6) 
 
1304  (36.2) 
977    (27.1) 
 
p<0.0001 
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   III 
   IVA 
   IVB 
   Missing 
1201  (22.0) 
355    (6.5) 
234    (4.3) 
849 
342   (18.5) 
103   (5.6) 
25     (1.4) 
-- 
859    (23.9) 
252    (7.0) 
209    (5.8) 
-- 
Surgery a 
  Yes 
  No 
 
6188   (98.2) 
109     (1.7) 
 
2125 (99.2) 
18     (0.8) 
 
4063  (97.8) 
91      (2.2) 
 
p<0.0001 
Extent of Thymectomy 
   None 
   Partial 
   Total 
   Extended 
   Missing 
 
140    (2.9) 
660    (13.4) 
3983  (81.1) 
130    (2.7) 
1384 
 
21      (1.4) 
78      (5.1) 
1393  (90.4) 
49      (3.2) 
-- 
 
119    (3.5)  
582    (17.3) 
2590  (76.8) 
81      (2.4) 
-- 
 
p<0.0001 
Chemotherapy 
   Curative b  
   Palliative/None 
   Missing 
 
1066  (20.3) 
4190  (79.7) 
1041 
 
233    (13.3) 
1525  (86.8) 
-- 
 
833    (23.8) 
2665  (76.2) 
-- 
 
p<0.0001 
Radiation 
   Curative b 
   Palliative/None 
   Missing 
 
2134  (41.9) 
2955  (58.1) 
1208 
 
700    (42.9) 
933    (57.1) 
-- 
 
1434  (41.5) 
2022  (58.5) 
-- 
 
p=0.35 
Resection Status 
   R0 
   R1 
   R2 
   Missing  
 
4768  (83.5) 
465    (8.1) 
480    (8.4) 
584 
 
1729  (87.2) 
165    (8.3) 
90      (4.5) 
-- 
 
3039  (81.5) 
300    (8.1) 
390    (10.5) 
-- 
 
p<0.0001 
Abbreviations: PN/AI (+) = presence of paraneoplastic autoimmune syndrome; PN/AI (-) = absence of paraneoplastic autoimmune 
syndrome; NETT = neuroendocrine tumors of the thymus 
Percentages calculated with exclusion of missing values and column percentages reported. 
a=Surgery field (Yes/No) was derived from many separate surgical fields from the database for completeness and accuracy.   
b=Curative includes neoadjuvant, adjuvant, and definitive (for chemotherapy, when given definitively with radiation). 
c=Other included 2 Cushing’s syndrome, 4 rheumatoid arthritis, and one each of anemia not otherwise specified, hemolytic anemia, 
erythrocytosis, thrombocytosis, neutropenia, polymyositis, Goodpasture syndrome, Grave’s disease, polymyalgia rheumatica. 
d=Of 42 PN/AI (+) thymic carcinoma, 38 had myasthenia gravis and 1 each of pure red cell aplasia, hypogammaglobulinemia, 
Cushing’s syndrome, and rheumatoid arthritis.  NETTs included 37 typical carcinoids, 55 atypical carcinoids, and 28 large cell or 
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small cell neuroendocrine carcinoma, 9 carcinoid NOS, and 10 others not further classified. All PN/AI (+) NETTs had myasthenia 
gravis and included 1 each of typical and atypical carcinoid and 3 poorly differentiated neuroendocrine carcinomas. 
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Table 2: Multivariate Analysis 
Characteristic Recurrence-Free 
Survival 
HR (95% CI)  
p-value Overall Survival 
 
HR (95% CI) 
p-value 
PN/AI 
  Present 
  Absent (ref) 
 
1.05 (0.82-1.34) 
1 
 
0.70 
 
1.10 (0.81-1.49) 
1 
 
0.54 
Age years 1.00 (1.00-1.02) b 0.02* 1.04 (1.03-1.05) 0.02* 
Sex 
   Female  
   Male (ref) 
 
0.96 (0.79-1.17) 
1 
 
0.68 
 
0.91 (0.71-1.17) 
1 
 
0.46 
Continent 
   North/South America 
   Asia 
   Europe (ref) 
 
0.94 (0.73-1.20) 
0.75 (0.57-0.97) 
1 
 
0.59 
0.03* 
 
0.82 (0.61-1.12) 
0.74 (0.54-1.02) 
1 
 
0.21 
0.07 
WHO Histology 
   A (ref) 
   AB 
   B1 
   B2 
   B3  
   Thymic Carcinoma 
   NETT    
 
1 
0.74 (0.47-1.16) 
0.77 (0.49-1.23) 
1.18 (0.78-1.80) 
1.17 (0.75-1.83) 
1.98 (1.27-3.07) 
2.19 (1.19-4.03) 
 
 
0.19 
0.28 
0.45 
0.50 
0.003* 
0.01* 
 
1 
0.82 (0.49-1.35) 
0.54 (0.31-0.95) 
0.89 (0.54-1.45) 
1.10 (0.66-1.86) 
1.99 (1.21-3.27) 
2.54 (1.26-5.12) 
 
 
0.43 
0.03* 
0.63 
0.71 
0.007* 
0.009* 
Pathologic Stage 
   I (ref) 
   II 
   III 
   IVA 
   IVB 
 
1 
1.18 (0.85-1.64) 
3.28 (2.35-4.59) 
4.42 (2.94-6.65) 
4.34 (2.66-7.06) 
 
 
0.33 
<0.0001* 
<0.0001* 
<0.0001* 
 
1 
0.94 (0.53-1.40) 
2.47 (1.67-3.67) 
2.63 (1.61-4.31) 
3.33 (1.86-5.98) 
 
 
0.75 
<0.0001* 
0.0001* 
<0.0001* 
Tumor Size 
(centimeters) 
1.03 (1.00-1.06) 0.03* 1.02 (0.99-1.06) 0.19 
Extent of Thymectomy 
   None (ref) 
   Partial 
   Total 
   Extended 
 
1 
0.96 (0.40-2.33) 
1.13 (0.49-2.58) 
1.96 (0.53-7.26) 
 
 
0.94 
0.78 
0.32 
 
1 
0.98 (0.37-2.60) 
0.99 (0.40-2.48) 
2.28 (0.52-9.99) 
 
 
0.97 
0.98 
0.28 
Chemotherapy 
   Curative a  
   Palliative/None (ref) 
 
1.30 (1.00-1.68) 
1 
 
0.05 
 
1.44 (1.05-1.97) 
1 
 
0.02* 
Radiation 
   Curative a 
   Palliative/None (ref) 
 
0.66 (0.52-0.83) 
1 
 
0.0003* 
 
0.61 (0.46-0.90) 
1 
 
0.0004* 
Resection Status 
   R0 (ref) 
   R1 
   R2 
 
1 
1.15 (0.85-1.56) 
1.50 (1.08-2.09) 
 
 
0.36 
0.02* 
 
1 
1.03 (0.69-1.52) 
1.59 (1.06-2.38) 
 
 
0.90 
0.02* 
Abbreviations: CI= confidence interval; HR = hazard ratio; PN/AI = paraneoplastic autoimmune syndrome; 
NETT = neuroendocrine tumors of the thymus 
*statistically significant (p<0.05) 
a= Curative includes neoadjuvant, adjuvant, and definitive (for chemotherapy, when given definitively with 
radiation). 
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b= 95% CI does not include 1 (1.001-1.016) 
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7795 patients in ITMIG retrospective database
6670 patients with known PN/AI status and final 
pathologic diagnosis
Excluded 373* 
• 287 surgery missing
• 47 WHO histology of 
Micronodular, Metaplastic, or 
Other
• 59 stage IV disease without 
further subgroup assignment 
(IVA vs. IVB)
6297 patients included in analysis
Excluded 1125 with missing PN/AI 
status or final pathologic diagnosis
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Cumulative incidence of 
recurrence (95% CI)
10-year 20-year 30-year 40-year
PN/AI (-) 0.21 (0.19-0.23) 0.28 (0.24-0.33) 0.39 (0.27-0.52) N/A 
PN/AI (+) 0.17 (0.15-0.20) 0.27 (0.22-0.33) 0.30 (0.23-0.37) 0.30 (0.28-0.37)
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PN/AI (+) vs. N/AI (-):
HR 0.63 (95% CI 0.54-0.74)
Median OS: 21.6 yrs vs. 17.0 yrs
Log-Rank test p<0.0001
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PN/AI (+) vs. PN/AI (-):
HR 0.82 (95% CI 0.70-0.97)
Median OS: 21.6 yrs vs. 18.7 yrs
Log-Rank test p=0.02
PN/AI (+) vs. PN/AI (-):
HR 0.56  (95% CI 0.29-1.10)
Median OS: 13.0 yrs vs. 7.4 yrs
Log-Rank test p=0.09
A B
